Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    evonik-m-2025-09-08

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Menu

    Repatha

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Expands Repatha Use to Adults at Risk of Cardiovascular Event
    FDA Expands Repatha Use to Adults at Risk of Cardiovascular Event

    28 Aug 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/fda-expands-repatha-indication-to-adults-at-risk-of-major-cardiovascular-events-from-uncontrolled-ldl-c-17677

    INDPHARMAPOST
    28 Aug 2025
    Share Share
    Amgen Expands Repatha® Use for High Cardiovascular Risk in Adults
    Amgen Expands Repatha® Use for High Cardiovascular Risk in Adults

    25 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/repatha-now-indicated-for-adults-at-increased-risk-for-major-adverse-cardiovascular-events-due-to-uncontrolled-ldl-c-302537326.html

    PR NEWSWIRE
    25 Aug 2025
    Share Share
    Amgen’s Biologics Repatha Receives Suppl Approval in US
    Amgen’s Biologics Repatha Receives Suppl Approval in US

    21 Aug 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125522

    FDA
    21 Aug 2025
    Share Share
    Amgen owes Regeneron $407M after defeat in PCSK9 antitrust suit
    Amgen owes Regeneron $407M after defeat in PCSK9 antitrust suit

    17 May 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/amgen-hook-pay-more-400m-after-regeneron-triumphs-cholesterol-drug-antitrust-suit

    FIERCE PHARMA
    17 May 2025
    Share Share
    Amgen`s Biologic Repatha Receives Suppl Approval in US
    Amgen`s Biologic Repatha Receives Suppl Approval in US

    20 Nov 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125522

    FDA
    20 Nov 2024
    Share Share
    Amgen`s Biologic Repatha (Evolocumab) Receives Suppl Approvals in US
    Amgen`s Biologic Repatha (Evolocumab) Receives Suppl Approvals in US

    19 Aug 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125522

    FDA
    19 Aug 2024
    Share Share